(1) If a pharmacy has entered into a collaborative pharmacy practice agreement with one or more physicians pursuant to section 12-280-602 to administer injectable antagonist medication for medication-assisted treatment for substance use disorders, the pharmacy administering the drug shall receive an enhanced dispensing fee.
If a pharmacy dispenses an opioid that is a schedule II or schedule III drug pursuantto section 18-18-204 or 18-18-205 to a patient who has not previously received an opioid prescription and the pharmacy provides counseling concerning the risk of opioids to the patient, the dispensing pharmacy shall receive an enhanced dispensing fee.
Subsection (2) of this section does not require a carrier to contract with a pharmacyor pharmacist willing to abide by the terms and conditions for participation established by the health benefit plan or carrier.
Source: L. 2018: Entire section added, (HB 18-1007), ch. 225, p. 1432, § 4, effective January 1, 2019. L. 2019: Entire section amended, (SB 19-228), ch. 276, p. 2601, § 1, effective May 23; entire section amended, (HB 19-1172), ch. 136, p. 1657, § 51, effective October 1.
Editor's note: Amendments to this section by SB 19-228 and HB 19-1172 were harmonized.